Incyte (STU:ICY) Change In Inventory : €-119 Mil (TTM As of Dec. 2024)

View and export this data going back to 1993. Start your Free Trial

What is Incyte Change In Inventory?

Incyte's change in inventory for the quarter that ended in Dec. 2024 was €-33 Mil. It means Incyte's inventory increased by €33 Mil from Sep. 2024 to Dec. 2024 .

Incyte's change in inventory for the fiscal year that ended in Dec. 2024 was €-122 Mil. It means Incyte's inventory increased by €122 Mil from Dec. 2023 to Dec. 2024 .

Incyte's Total Inventories for the quarter that ended in Dec. 2024 was €56 Mil.

Days Inventory indicates the number of days of goods in sales that a company has in the inventory. Incyte's Days Inventory for the quarter that ended in Dec. 2024 was 64.61.

Inventory Turnover measures how fast the company turns over its inventory within a year. Incyte's Inventory Turnover for the quarter that ended in Dec. 2024 was 1.41.

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Incyte's Inventory-to-Revenue for the quarter that ended in Dec. 2024 was 0.05.

Incyte Change In Inventory Historical Data

The historical data trend for Incyte's Change In Inventory can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Incyte Change In Inventory Chart

Incyte Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Change In Inventory

Get a 7-Day Free Trial

-16.00

-18.55

-63.72

-156.03

-121.89

Incyte Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Change In Inventory	Get a 7-Day Free Trial															-85.24	-52.62	-25.81	-7.55	-32.74

Incyte Change In Inventory Calculation

Change In Inventory is the difference between last period's ending inventory and the current period's ending inventory.

Change In Inventory for the trailing twelve months (TTM) ended in Dec. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was €-119 Mil.

Incyte (STU:ICY) Change In Inventory Explanation

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Incyte's Days Inventory for the quarter that ended in is calculated as:

Days Inventory	=	Average Total Inventories	/	Cost of Goods Sold	*	Days in Period
	=	59.8455	/	84.518	*	365 / 4
	=	64.61

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Incyte's Inventory Turnover for the quarter that ended in Dec. 2024 is calculated as

Inventory Turnover	=	Cost of Goods Sold	/	Average Total Inventories
	=	84.518	/	59.8455
	=	1.41

3. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Incyte's Inventory to Revenue for the quarter that ended in Dec. 2024 is calculated as

Inventory-to-Revenue	=	Average Total Inventories	/	Revenue
	=	59.8455	/	1125.657
	=	0.05

Incyte Change In Inventory Related Terms

Thank you for viewing the detailed overview of Incyte's Change In Inventory provided by GuruFocus.com. Please click on the following links to see related term pages.

Incyte Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Incyte Corp (STU:ICY) » Definitions » Change In Inventory

Comparable Companies

Traded in Other Exchanges

INCY:USA INCY:Mexico 1INCY:Italy 0J9P:UK ICY:Germany

Address

1801 Augustine Cut-Off, Wilmington, DE, USA, 19803

Website

https://www.incyte.com

Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes a broad array of oncology and dermatology programs.

Incyte Headlines

No Headlines